Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors

International Journal of Radiation Biology

Volumn 88, Issue 3, 2012, Pages 277-285

  Rockwell, Sara ^a   Liu, Yanfeng ^a   Seow, Helen A ^a   Ishiguro, Kimiko ^a   Baumann, Raymond P ^a   Penketh, Philip G ^a   Shyam, Krishnamurthy ^a   Akintujoye, Oluwatoyin M ^a   Glazer, Peter M ^a   Sartorelli, Alan C ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

Combined modalities; Experimental radiotherapy; Laromustine; O 6 Alkylguanine DNA transferase; Onrigin; Radiation

Indexed keywords

LAROMUSTINE;

ARTICLE; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COMBINED MODALITY THERAPY; CRICETINAE; DNA REPAIR; HUMANS; HYDRAZINES; MAMMARY NEOPLASMS, ANIMAL; MICE; NEOPLASMS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; RADIATION TOLERANCE; SULFONAMIDES; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

CRICETULUS GRISEUS; MUS;

EID: 84863242419     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553002.2012.638359     Document Type: Article

References (32)

1. 6-alkylguanine-DNA alkyltransferase mediated KS119 tumor cell resistance. Biochemical Pharmacology 79:1553-15561.
2. TM is produced by the synergistic interaction of carbamoylating and alkylating products of its activation. Oncology Research 15:313-325. (Pubitemid 43074226)
3. 6-alkylguanine-DNA alkyltransferase in cytotoxicity. Cancer Chemotherapy Pharmacology 53:288-295. (Pubitemid 38392353)
4. Donnelly ET, Liu Y, Rockwell S. 2006. Efaproxiral (RSR13) plus oxygen breathing increases the therapeutic ratio of carboplatin in EMT6 mouse mammary tumors. Experimental Biology and Medicine 231:317-321. (Pubitemid 43334318)
5. Finch RA, Shyam K, Penketh PG, Sartorelli AC. 2001. 1,2- Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino) carbonylhydrazine (101M): A novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity. Cancer Research 61:3033-3038. (Pubitemid 32691951)
6. Frederick AM, Davis ML, Rice K P. 2009. Inhibition of human DNA polymerase β activity by the anticancer prodrug Cloretazine. Biochemical and Biophysical Research Communications 378:419-423.
7. Giles FJ. 2007. Bendamustine and cloretazine: Alkylators with sharply contrasting activity in AML. Leukemia & Lymphoma 48:1064-1066. (Pubitemid 47009194)
8. Giles F, Rizzieri D, Karp J, Vey N, Ravandi F, Faderl S, Khan KD, Verhoef G, Wijermans P, Advani A, Roboz G, Kantarjian H, Bilgrami SF, Ferrant A, Daenen SM, Karsten V, Cahill A, Albitar M, Mufti G, O'Brien S. 2007. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. Journal of Clinical Oncology 25:25-31. (Pubitemid 350003047)
9. Hahn GM, Rockwell S, Kallman RF, Gordon LF, Frindel E. 1974. Repair of potentially lethal damage in vivo in solid tumor cells after x-irradiation. Cancer Research 34:351-354.
10. Ishiguro K, Seow HA, Penketh PG, Shyam K, Sartorelli AC. 2006. Mode of action of the chloroethylating and carbamoylating moieties of the produrg cloretazine. Molecular Cancer Terapy 5:969-976. (Pubitemid 43724597)
11. 6-alkylguanine-DNA alkyltransferase in the cytotoxic activity of clore-tazine. Molecular Cancer Terapy 5:1755-1763. (Pubitemid 41685310)
12. 6- alkylguanine-DNA alkyltransferance. Biochemical Pharmacology 80:1317-1325.
13. Li SX, Sjolund A, Harris L, Sweasy JB. 2010. DNA repair and personalized breast cancer therapy. Environmental and Molecular Mutagenesis 51:897-908.
14. Moulder JE, Rockwell S. 1987. Tumor hypoxia: Its impact on cancer therapy. Cancer and Metastasis Reviews 5:313-341.
15. Murren J, Modiano M, Kummar S, Clairmont C, Egorin M, Chu E, Sznol M. 2005. A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer. Investigational New Drugs 23:123-135. (Pubitemid 40386229)
16. Paz MM, Ladwa S, Champeil E, Liu Y, Rockwell S, Boamah EK, Bargonetti J, Callahan J, Roach J, Tomasz M. 2008. Mapping DNA adducts of mitomycin C and decarbamoyl mitomycin C in cell lines using liquid chromatography electrospray tandem mass spectrom-etry. Chemical Research Toxicology 21:2370-2378.
17. Penketh PG, Shyam K, Sartorelli AC. 2000. Comparison of DNA lesions produced by tumor-inhibitory 1,2-Bis(sulfonyl)hydrazines and chloroethylnitrosoureas. Biochemical Pharmacology 59:283-291. (Pubitemid 30001755)
18. 6- alkylguanine-DNA alkyltransferase (AGT) by electrophilic species generated by decomposition. Cancer Chemotherapy and Pharmacology 53:279-287. (Pubitemid 38392352)
19. Penketh PG, Baumann RP, Ishiguro K, Shyam K, Seow HA, Sartorelli AC. 2008. Lethality to leukemia cell lines of DNA interstrand crosslinks generated by Cloretazine derived alkylating species. Leukemia Research 32:1546-1553.
20. Ray GR, Hahn GM, Bagshaw MA, Kurkjian S. 1973. Cell survival and repair of plateau-phase cultures after chemotherapy; relevance to tumor therapy and to the in vitro screening of new agents. Cancer Chemotherapy Reports 57:473-475.
21. TM and BCNU. Biochemical Pharmacology 69:1463-1472. (Pubitemid 40602446)
22. Rockwell S. 1977. In vivo-in vitro tumor systems: New model for studying the response of tumors to therapy. Laboratory Animal Science 27:831-851. (Pubitemid 8255715)
23. Rockwell S, Dobrucki IT, Kim EY, Vu V. 2009. Hypoxia and radiation therapy: Past history, ongoing research, and future promise. Current Molecular Medicine 9:442-458.
24. Rockwell S, Hughes CS. 1994. Effects of mitomycin C and porf romycin on exponentially growing and plateau phase cultures. Cell Proliferation 27:153-163. (Pubitemid 24078232)
25. Rockwell S, Kallman RF, Fajardo LF. 1972. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. Journal of the National Cancer Institute 49:735-749.
26. Rockwell S, Liu Y. 2010. Aplidin as a potential adjunct to radiation therapy: In vitro studies. International Journal of Radiation Biology 86:63-70.
27. Shyam K, Penketh PG, Loomis RH, Rose WC, Sartorelli AC. 1996. Antitu-mor 2-(aminocarbonyl)-1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-hydrazines. Journal of Medicinal Chemistry 39:796-801.
28. Steel GG. 1979. Terminology in the description of drug-radiation interactions. International Journal of Radiation Oncology Biology and Physics 5:1145-1150. (Pubitemid 10215318)
29. Steensma DP. 2010. Novel therapies for myelodysplastic syndromes. Hematology and Oncology Clinics of North America 24:423-441.
30. Teicher BA, Lazo JS, Sartorelli AC. 1981. Classif cation of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Research 41:73-81. (Pubitemid 11218796)
31. Twentyman PR, Bleehen NM. 1975. Changes in sensitivity to cyto-toxic agents occurring during the life history of monolayer cultures of a mouse tumour cell line. British Journal of Cancer 31:417-423.
32. Vey N, Giles F. 2010. Laromustine (cloretazine). Expert Opinions in Pharmacotherapy 11:657-667.